Niche CRO Atlantic Bone Screen specializes in preclinical evaluation for inflammation, osteoarticular diseases and skin conditions, offering in vitro, in vivo, histology, and imaging services. This positions them as a targeted partner for biotech and pharma firms developing bone-related therapies, cosmetics ingredients, nutraceuticals, or dental materials.

Bone Platform With in-house rodent facilities and a suite of bone and joint models (osteoporosis, arthritis, rheumatoid arthritis, bone cancer), they can support early safety, efficacy, and translational studies, presenting a compelling value proposition to firms needing robust preclinical data quickly.

End-to-End Capabilities span primary human/animal cells, histopathology, tissue imaging, multi-organ toxicity assessments, and microCT imaging, enabling a single CRO to cover multiple preclinical endpoints, potentially reducing vendor fragmentation and speeding project timelines.

Small Team, Niche With 11-50 employees and revenue under 1M, ATLANTIC BONE SCREEN can be a cost-effective, agile partner for early-stage programs, offering personalized service and rapid communication, which may be attractive to startups and small biotech companies.

Growth Synergies The existence of a sister company, ATLANTHERA, suggests cross-selling opportunities in bone research and drug discovery services. Joint engagements could expand scope to early discovery and translational preclinical work, increasing overall account value.